Global Diabetes Drugs Market 2017-2023 - Revenue and Market Share Analysis by Company

Dublin, Nov. 14, 2017 -- The "Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes" report has been added to Research and Markets' offering.

Global Diabetes Drugs Market to 2023 comprehensively reviews the strategies of key players in the DM market, and provides market share forecasts. Pipeline and marketed products are analyzed in detail, along with the impact that products expected to come to market between 2016 and 2023 will have on existing established products. Licensing and co-marketing deals in DM are analyzed by region and value.

The DM market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter 2 (SGLT-2) inhibitors. Increased market diversification is expected to continue throughout the forecast period due to patent expiries for major insulin products and increased uptake of non-insulin drugs.

Incidence of diabetes mellitus (DM), and most notably type 2 diabetes mellitus (T2DM), which accounts for more than 90% of all DM cases, is growing rapidly on a global scale. The US is expected to experience the greatest rise in T2DM prevalence, and incidence rates are also expected to increase to about 4% by 2023. Several factors are driving the increase of T2DM, with aging population and the prevalence of highly calorific diets being some of the key drivers.

In 2016, the top five products, all of which are insulin products, commanded almost half of the market by sales. By 2023, the top 10 products are expected to occupy more than 40% of the market share, many of which will be non-insulin products.

Competition will intensify over the forecast period as more companies enter the DM market space. However, Novo Nordisk, which is currently the leading player in terms of market share, is expected to maintain its position throughout the forecast period. Despite declining revenues for high-grossing products such as Levemir (insulin detemir), more recent market additions such as Tresiba (insulin degludec), as well as the upcoming pipeline products such as semaglutide and oral semaglutide are expected to more than compensate.

Key Topics Covered:

1. List of Tables & Figures

2 Introduction

• Classification of Diabetes
• Symptoms
• Diagnostic Criteria
• Etiology
• Pathophysiology
• Epidemiology
• Comorbidities and Complications
• Treatments

3 Key Marketed Products

• Overview
• Long-Acting Insulin Therapies (Basal Insulins)
• Short-Acting Insulin Therapies (Bolus Insulins)
• GLP-1 Receptor Agonists
• DPP-4 Inhibitors
• SGLT-2 Inhibitors
• Combination Therapies
• Unmet Needs
• Conclusion

4 Pipeline Landscape Assessment

• Pipeline Development Landscape
• Molecular Targets in the Pipeline
• Clinical Trials Landscape
• Assessment of Key Pipeline Products

5 Multi-scenario Market Forecast to 2023

• Overall Market Size
• Generic Penetration
• Revenue Forecast by Molecular Target

6 Company Analysis and Positioning

• Revenue and Market Share Analysis by Company
• Novo Nordisk - Sales from Recently Approved and Upcoming Products to Increase Already Substantial Market Share
• Eli Lilly - Strong Growth to Result in Elevation to Second Place in Market
• Sanofi - Large Market Share Loss Due to Declining Sales of Lantus
• AstraZeneca - Growth in Revenue Largely Attributable to Farxiga Sales
• Johnson and Johnson - Continued Uptake of Invokana to Drive Market Growth
• Merck & Co - Patent Expiry of Januvia to Limit Growth
• Company Landscape
• Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/p3wqzb/global_diabetes

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Endocrine and Metabolic Disorders Drugs